Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company that has historically focused on developing drug candidates and, more recently, has expanded into in-licensed diagnostic tests. The company has no approved commercial pharmaceutical products and is still in a development-stage, capital-dependent profile, with operations funded primarily through equity, warrants, and other financing instruments.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaResearch, preclinical work, and clinical development of drug candidates and related technologies.
Diagnostic tests licensed from New Day Diagnostics, including celiac, respiratory multiplex, H. pylori, and HCC tests.
Rights to sell CE-marked diagnostic products in Europe and pursue regulatory, sales, and reimbursement milestones.
Asiakkaat
Hepion’s historical customer base is not a traditional recurring buyer base because the company has not generated operating revenue from its pharmaceutical programs. Its near-term commercial opportunity is tied to European buyers of CE-marked diagnostic tests, including healthcare providers, laboratories, and distributors, while future pharmaceutical customers would be patients and prescribers if a product is approved.
Hospitals, labs, and distributors that can purchase CE-marked celiac, respiratory multiplex, and H. pylori tests for immediate sale in Europe.
Clinical end users that would adopt the tests based on workflow fit, turnaround time, and disease screening needs.
Organizations that affect pricing, reimbursement, and scale-up of diagnostic sales in target markets.
Potential end users of any approved drug candidate from Hepion’s development pipeline.
Strategia
Hepion’s strategy has shifted from a pure drug-development model toward strategic alternatives and in-licensed diagnostics that can be commercialized sooner. Management is focused on preserving liquidity, reducing burn, and creating a path to revenue through CE-marked products while still retaining optionality around future development assets.
These products are the only disclosed near-term revenue opportunity and can generate sales before any drug approval.
The company has no operating revenue and must fund ongoing development, licensing, and commercialization activities.
Lower cash usage extends runway and supports execution while the company transitions its business model.
Management continues to evaluate acquisitions, licensing, and other alternatives to rebuild the pipeline.
Maantiede
Hepion is headquartered in the United States, but its disclosed near-term commercialization opportunity is in Europe because three licensed diagnostic products have CE marks and are eligible for sale there. The company currently has no commercial products approved for sale in the U.S., so geography matters mainly through regulatory access, reimbursement, and the ability to build a European sales channel.
Riskit
Hepion remains a high-risk, development-stage company with no approved commercial products and a history of operating losses. Its ability to continue depends on raising capital, successfully commercializing licensed diagnostics, and navigating regulatory and reimbursement hurdles in Europe and beyond.
- Going-concern and liquidity riskVaikutus: KriittinenTodennäköisyys: Korkea
The company has no approved products and expects continued losses, so it may need additional capital to operate.
Kohdistuu: All operations
- Regulatory approval and compliance riskVaikutus: KorkeaTodennäköisyys: Korkea
Commercialization depends on meeting FDA and foreign regulatory requirements, and approvals can be delayed, limited, or withdrawn.
Kohdistuu: Drug candidates and diagnostics
- Commercialization and reimbursement riskVaikutus: KorkeaTodennäköisyys: Korkea
Even CE-marked products may not generate meaningful revenue if adoption, pricing, or reimbursement is weak.
Kohdistuu: European diagnostics
- Dilution risk from capital raisesVaikutus: KorkeaTodennäköisyys: Korkea
Funding has come from equity, warrants, and preferred stock, which can dilute existing shareholders.
Kohdistuu: Capital structure
- Development failure riskVaikutus: KorkeaTodennäköisyys: Korkea
Pharmaceutical candidates can fail in preclinical or clinical testing or prove unsafe or ineffective.
Kohdistuu: Pipeline assets
Kirjanpito
Harkinnanvaraiset erätWarrants and other embedded features are remeasured, creating non-cash gains or losses that can dominate earnings.
Vaikutus: Reported net loss can change materially period to period.
Milestone-based obligations tied to licensing or acquisitions require valuation estimates and periodic remeasurement.
Vaikutus: Can increase liabilities and create volatility in other income/expense.
Development assets may be written down if expected future benefits decline or programs are discontinued.
Vaikutus: Can reduce asset values and increase operating loss.
Preferred stock, warrants, and pre-funded warrants affect share count, APIC, and dilution analysis.
Vaikutus: Important for per-share metrics and capital structure interpretation.
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
HCW Biologics Inc.
HCWB · Pharmaceutical Preparations
Ocean Biomedical, Inc.
OCEA · Pharmaceutical Preparations
Eledon Pharmaceuticals, Inc.
ELDN · Pharmaceutical Preparations
Enanta Pharmaceuticals, Inc
ENTA · Pharmaceutical Preparations
Enanta Pharmaceuticals is a U.S.-based biotechnology company focused on discovering and developing small-molecule drugs in virology and immunology.
Atea Pharmaceuticals, Inc.
AVIR · Pharmaceutical Preparations
Celcuity Inc.
CELC · Services-Medical Laboratories
Päivitetty: 24.9.2026